Skip to main content
Erschienen in: Cancer Causes & Control 4/2013

01.04.2013 | Original paper

Prevalence of type-specific human papillomavirus and pap results in Chinese women: a multi-center, population-based cross-sectional study

verfasst von: En-Qi Wu, Bin Liu, Jian-Feng Cui, Wen Chen, Jian-Bing Wang, Liang Lu, Mayineur Niyazi, Chao Zhao, Sheng-Da Ren, Chang-Qing Li, Xiang-Zhen Gong, Jennifer S. Smith, Jerome L. Belinson, Kai-Li Liaw, Christine Velicer, You-Lin Qiao

Erschienen in: Cancer Causes & Control | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To estimate the burden of human papillomavirus (HPV) infection among sexually active women in China.

Methods

We conducted a multi-center, population-based study between May 2006 and April 2007. A total of 4,215 women aged 17–54 years were surveyed from five geographical sites: Beijing, Shanghai, Shanxi, Henan, and Xinjiang. Direct endocervical exfoliated cells were collected from consenting participants for Sure Path liquid-based cytology (BD) and HPV testing. HPV testing was performed with Hybrid Capture II (Qiagen) with high-risk and low-risk probes, and Linear Array (Roche) was utilized for HPV genotyping.

Results

Approximately 11 % of the study population had a cytological abnormality (ASCUS or worse). HPV prevalence in the entire study population was 14.3 % (age-standardized to the world standard female population 14.5 %). The most prevalent types found were HPV16 (2.9 %), HPV52 (1.7 %), HPV58 (1.5 %), HPV33 (1 %), and HPV18 (0.8 %). Patterns of HPV prevalence differed by age, geographic region, and cytology findings. However, HPV16 was predominant among all grades of cytological abnormalities for all areas.

Conclusions

Although HPV18 appeared to be less frequent among population-based samples of China, given the high prevalence of HPV 16 and 18 in high-grade squamous intraepithelial lesion (HSIL) or worse pap abnormalities, prophylactic HPV16/18 vaccines should substantially reduce the burden of cervical cancer in China.
Literatur
2.
Zurück zum Zitat Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. (2010) GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. (2010) GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC Cancer Base No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://​globocan.​iarc.​fr
3.
Zurück zum Zitat Canfell K, Shi JF, Lew JB, Walker R, Zhao FH, Simonella L, Chen JF, Legood R, Smith MA, Nickson C, Qiao YL (2011) Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies. Vaccine 29(13):2487–2494. doi:10.1016/j.vaccine.2010.12.085 PubMedCrossRef Canfell K, Shi JF, Lew JB, Walker R, Zhao FH, Simonella L, Chen JF, Legood R, Smith MA, Nickson C, Qiao YL (2011) Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies. Vaccine 29(13):2487–2494. doi:10.​1016/​j.​vaccine.​2010.​12.​085 PubMedCrossRef
5.
8.
Zurück zum Zitat Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348(6):518–527. doi:10.1056/NEJMoa021641 PubMedCrossRef Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348(6):518–527. doi:10.​1056/​NEJMoa021641 PubMedCrossRef
9.
Zurück zum Zitat Garland S, Park SN, Ngan HY, Frazer I, Tay EH, Chen CJ, Bhatla N, Pitts M, Shin HR, Konno R, Smith J, Pagliusi S, Park JS (2008) The need for public education on HPV and cervical cancer prevention in Asia. Opinions of experts at the AOGIN conference. Vaccine 26(43):5435–5440. doi:10.1016/j.vaccine.2008.07.077 PubMedCrossRef Garland S, Park SN, Ngan HY, Frazer I, Tay EH, Chen CJ, Bhatla N, Pitts M, Shin HR, Konno R, Smith J, Pagliusi S, Park JS (2008) The need for public education on HPV and cervical cancer prevention in Asia. Opinions of experts at the AOGIN conference. Vaccine 26(43):5435–5440. doi:10.​1016/​j.​vaccine.​2008.​07.​077 PubMedCrossRef
10.
Zurück zum Zitat Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18 follow-up from a randomised control trial. Lancet 367(9518):1247–1255PubMedCrossRef Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18 follow-up from a randomised control trial. Lancet 367(9518):1247–1255PubMedCrossRef
11.
Zurück zum Zitat The FUTURE II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (19):1915–1927. doi:10.1056/NEJMoa061741 The FUTURE II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356 (19):1915–1927. doi:10.​1056/​NEJMoa061741
12.
Zurück zum Zitat Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121(3):621–632. doi:10.1002/ijc.22527 PubMedCrossRef Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121(3):621–632. doi:10.​1002/​ijc.​22527 PubMedCrossRef
15.
Zurück zum Zitat Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat (2009). World population prospects: The 2008 Revision. Highlights. New York: United Nations. Available from http://www.un.org/esa/population Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat (2009). World population prospects: The 2008 Revision. Highlights. New York: United Nations. Available from http://​www.​un.​org/​esa/​population
16.
Zurück zum Zitat Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S (2010) Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202(12):1789–1799. doi:10.1086/657321 PubMedCrossRef Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, de Sanjose S (2010) Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202(12):1789–1799. doi:10.​1086/​657321 PubMedCrossRef
17.
Zurück zum Zitat Dai M, Bao YP, Li N, Clifford GM, Vaccarella S, Snijders PJ, Huang RD, Sun LX, Meijer CJ, Qiao YL, Franceschi S (2006) Human papillomavirus infection in Shanxi Province, People’s Republic of China: a population-based study. Br J Cancer 95(1):96–101. doi:10.1038/sj.bjc.6603208 PubMedCrossRef Dai M, Bao YP, Li N, Clifford GM, Vaccarella S, Snijders PJ, Huang RD, Sun LX, Meijer CJ, Qiao YL, Franceschi S (2006) Human papillomavirus infection in Shanxi Province, People’s Republic of China: a population-based study. Br J Cancer 95(1):96–101. doi:10.​1038/​sj.​bjc.​6603208 PubMedCrossRef
18.
Zurück zum Zitat Wu RF, Dai M, Qiao YL, Clifford GM, Liu ZH, Arslan A, Li N, Shi JF, Snijders PJ, Meijer CJ, Franceschi S (2007) Human papillomavirus infection in women in Shenzhen City, People’s Republic of China, a population typical of recent Chinese urbanisation. Int J Cancer 121(6):1306–1311. doi:10.1002/ijc.22726 PubMedCrossRef Wu RF, Dai M, Qiao YL, Clifford GM, Liu ZH, Arslan A, Li N, Shi JF, Snijders PJ, Meijer CJ, Franceschi S (2007) Human papillomavirus infection in women in Shenzhen City, People’s Republic of China, a population typical of recent Chinese urbanisation. Int J Cancer 121(6):1306–1311. doi:10.​1002/​ijc.​22726 PubMedCrossRef
19.
Zurück zum Zitat Li LK, Dai M, Clifford GM, Yao WQ, Arslan A, Li N, Shi JF, Snijders PJ, Meijer CJ, Qiao YL, Franceschi S (2006) Human papillomavirus infection in Shenyang City, People’s Republic of China: a population-based study. Br J Cancer 95(11):1593–1597. doi:10.1038/sj.bjc.6603450 PubMedCrossRef Li LK, Dai M, Clifford GM, Yao WQ, Arslan A, Li N, Shi JF, Snijders PJ, Meijer CJ, Qiao YL, Franceschi S (2006) Human papillomavirus infection in Shenyang City, People’s Republic of China: a population-based study. Br J Cancer 95(11):1593–1597. doi:10.​1038/​sj.​bjc.​6603450 PubMedCrossRef
21.
Zurück zum Zitat Ye J, Cheng X, Chen X, Ye F, Lu W, Xie X (2010) Prevalence and risk profile of cervical Human papillomavirus infection in Zhejiang Province, southeast China: a population-based study. Virol J 7:66. doi:10.1186/1743-422X-7-66 PubMedCrossRef Ye J, Cheng X, Chen X, Ye F, Lu W, Xie X (2010) Prevalence and risk profile of cervical Human papillomavirus infection in Zhejiang Province, southeast China: a population-based study. Virol J 7:66. doi:10.​1186/​1743-422X-7-66 PubMedCrossRef
22.
Zurück zum Zitat Munoz N, Mendez F, Posso H, Molano M, van den Brule AJ, Ronderos M, Meijer C, Munoz A (2004) Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 190(12):2077–2087. doi:10.1086/425907 PubMedCrossRef Munoz N, Mendez F, Posso H, Molano M, van den Brule AJ, Ronderos M, Meijer C, Munoz A (2004) Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 190(12):2077–2087. doi:10.​1086/​425907 PubMedCrossRef
23.
Zurück zum Zitat Dutra I, Santos MR, Soares M, Couto AR, Bruges-Armas M, Teixeira F, Monjardino L, Hodgson S, Bruges-Armas J (2008) Characterisation of human papillomavirus (HPV) genotypes in the Azorean population Terceira island. Infect Agent Cancer 3:6. doi:10.1186/1750-9378-3-6 PubMedCrossRef Dutra I, Santos MR, Soares M, Couto AR, Bruges-Armas M, Teixeira F, Monjardino L, Hodgson S, Bruges-Armas J (2008) Characterisation of human papillomavirus (HPV) genotypes in the Azorean population Terceira island. Infect Agent Cancer 3:6. doi:10.​1186/​1750-9378-3-6 PubMedCrossRef
24.
Zurück zum Zitat Zhao R, Zhang WY, Wu MH, Zhang SW, Pan J, Zhu L, Zhang YP, Li H, Gu YS, Liu XZ (2009) Human papillomavirus infection in Beijing, People’s Republic of China: a population-based study. Br J Cancer 101(9):1635–1640. doi:10.1038/sj.bjc.6605351 PubMedCrossRef Zhao R, Zhang WY, Wu MH, Zhang SW, Pan J, Zhu L, Zhang YP, Li H, Gu YS, Liu XZ (2009) Human papillomavirus infection in Beijing, People’s Republic of China: a population-based study. Br J Cancer 101(9):1635–1640. doi:10.​1038/​sj.​bjc.​6605351 PubMedCrossRef
25.
Zurück zum Zitat Coutlee F, Gravitt P, Kornegay J, Hankins C, Richardson H, Lapointe N, Voyer H, Franco E (2002) Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J Clin Microbiol 40(3):902–907PubMedCrossRef Coutlee F, Gravitt P, Kornegay J, Hankins C, Richardson H, Lapointe N, Voyer H, Franco E (2002) Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J Clin Microbiol 40(3):902–907PubMedCrossRef
26.
Zurück zum Zitat Chan PK, Cheung TH, Tam AO, Lo KW, Yim SF, Yu MM, To KF, Wong YF, Cheung JL, Chan DP, Hui M, Ip M (2006) Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int J Cancer 118(1):243–245. doi:10.1002/ijc.21299 PubMedCrossRef Chan PK, Cheung TH, Tam AO, Lo KW, Yim SF, Yu MM, To KF, Wong YF, Cheung JL, Chan DP, Hui M, Ip M (2006) Biases in human papillomavirus genotype prevalence assessment associated with commonly used consensus primers. Int J Cancer 118(1):243–245. doi:10.​1002/​ijc.​21299 PubMedCrossRef
27.
Zurück zum Zitat de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7(7):453–459. doi:10.1016/S1473-3099(07)70158-5 PubMedCrossRef de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX (2007) Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 7(7):453–459. doi:10.​1016/​S1473-3099(07)70158-5 PubMedCrossRef
28.
Zurück zum Zitat Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J, Alfaro M, Sherman ME, Wacholder S, Chen S, Rodriguez AC, Burk RD (2005) Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste Costa Rica. J Infect Dis 191(11):1796–1807. doi:10.1086/428850 PubMedCrossRef Herrero R, Castle PE, Schiffman M, Bratti MC, Hildesheim A, Morales J, Alfaro M, Sherman ME, Wacholder S, Chen S, Rodriguez AC, Burk RD (2005) Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste Costa Rica. J Infect Dis 191(11):1796–1807. doi:10.​1086/​428850 PubMedCrossRef
29.
Zurück zum Zitat Cuschieri KS, Cubie HA, Whitley MW, Seagar AL, Arends MJ, Moore C, Gilkisson G, McGoogan E (2004) Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol 57(1):68–72PubMedCrossRef Cuschieri KS, Cubie HA, Whitley MW, Seagar AL, Arends MJ, Moore C, Gilkisson G, McGoogan E (2004) Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol 57(1):68–72PubMedCrossRef
Metadaten
Titel
Prevalence of type-specific human papillomavirus and pap results in Chinese women: a multi-center, population-based cross-sectional study
verfasst von
En-Qi Wu
Bin Liu
Jian-Feng Cui
Wen Chen
Jian-Bing Wang
Liang Lu
Mayineur Niyazi
Chao Zhao
Sheng-Da Ren
Chang-Qing Li
Xiang-Zhen Gong
Jennifer S. Smith
Jerome L. Belinson
Kai-Li Liaw
Christine Velicer
You-Lin Qiao
Publikationsdatum
01.04.2013
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 4/2013
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-013-0162-8

Weitere Artikel der Ausgabe 4/2013

Cancer Causes & Control 4/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.